News
CTXRW
0.1441
+561.01%
0.1223
CITIUS PHARMACEUTICALS ANNOUNCES $15 MILLION REGISTERED DIRECT OFFERING
Reuters · 13h ago
CITIUS PHARMACEUTICALS ANNOUNCES ADDITION OF CITY OF HOPE TO UMN'S PHASE 1 TRIAL OF LYMPHIR IN COMBINATION WITH CAR-T FOR THE TREATMENT OF B-CELL LYMPHOMA
Reuters · 04/11 12:30
Citius Pharmaceuticals Inc reports results for the quarter ended in December - Earnings Summary
Citius Pharmaceuticals Inc reports results for the quarter ended in December. The company reported a quarterly adjusted loss of 6 cents per share. The average analyst rating on the company's shares is "buy" Citius pharmaceuticals Inc shares had fallen by 10.1% this quarter.
Reuters · 02/14 23:57
Citius Pharmaceuticals Inc <CTXR.OQ> expected to post earnings of 13 cents a share - Earnings Preview
Citius Pharmaceuticals Inc expected to post earnings of 13 cents a share. The Cranford New Jersey-based company is expected to report revenue of $21.295 million for the period ending December 31 2023. Average analyst rating on the shares is "buy"
Reuters · 02/06 11:04
Citius Pharmaceuticals Inc reports results for the quarter ended in September - Earnings Summary
Citius Pharmaceuticals Inc reports results for the quarter ended in September. The company reported a quarterly adjusted loss of 8 cents per share. The mean expectation of two analysts was for a loss of 7 cents. The average analyst rating on the company's shares is "buy"
Reuters · 12/29/2023 23:27
Citius Pharmaceuticals Inc <CTXR.OQ> expected to post a loss of 2 cents a share - Earnings Preview
Citius Pharmaceuticals Inc expected to post a loss of 2 cents a share - Earnings Preview. The company is expected to show change in quarterly revenue when it reports results on December 20. LSEG's mean analyst estimate for the company is for a quarterly loss of 2 cents per share.
Reuters · 12/18/2023 11:03
BUZZ-U.S. STOCKS ON THE MOVE-Asbury, natgas firms, energy firms
Reuters · 09/08/2023 15:46
BUZZ-Citius Pharma up on plans to resubmit marketing application for cancer drug
Reuters · 09/08/2023 13:38
BRIEF-Citius Pharmaceuticals Inc. Reports Fiscal Second Quarter 2023 Financial Results
Reuters · 05/12/2023 20:38
More
Webull provides a variety of real-time CTXRW stock news. You can receive the latest news about Citius Pharmaceuticals Inc through multiple platforms. This information may help you make smarter investment decisions.
About CTXRW
Citius Pharmaceuticals, Inc. is a late-stage biopharmaceutical company. It develops and commercializes critical care products with a focus on oncology, anti-infectives in adjunct cancer care, prescription products and stem cell therapy. Its products include LYMPHIR, Mino-Lok, Halo-Lido, NoveCite and Mino-Wrap. LYMPHIR is an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma. Mino-Lok is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections by salvaging the infected catheter. Halo-Lido is a corticosteroid-lidocaine topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids. Mino-Wrap is a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries. NoveCite is a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome.